Media Report
Jiaxing Angel pharmaceutical R&D center launched.New progress in biomedical industry of Jiaxing Science and Technology Zone
News from Hedian, July 22, 2002 (media news center reporter Zheng Shengzhong, Cao Zhi, Zhao Tianyi (Internship))
This (July 22) morning, Angel pharmaceutical R&D center opening ceremony were held in the Jiaxing future . Technology Institute
Since the "cloud contract" at the end of April last year, Jiaxing Angel pharmaceutical industry has developed rapidly. The R & D center of Jiaxing headquarters has a total area of more than 3000 square meters, with complete biological and chemical innovative drug research and development laboratories and complete drug analysis equipment, which will greatly accelerate the expansion of innovative drug pipeline of pharmaceutical industry in the future. At the same time, Hutchison's R&D center in San Francisco, USA, has been launched at the same time, attracting a number of industry senior people to join in, and build a team of early research and development, clinical development and drug manufacturing of innovative drugs across China and the United States. Angel pharmaceutical has also established a comprehensive cooperative relationship with top domestic medical institutions such as Peking University Cancer Hospital and Shanghai Oriental Hospital in translational medicine and clinical research, so as to rapidly promote the clinical development process of pipeline drugs in China.
At present, Jiaxing Angel Pharmaceutical Co., Ltd. has a global patent for innovative drugs, focusing on major public health drug demand fields such as cancer and autoimmune. CPI-818, the world's first ITK inhibitor for T-cell lymphoma, submitted a clinical approval application to the drug examination center of the State Food and Drug Administration in July 2021. It is expected that the patients will be enrolled in this year and will join the global phase II clinical trial in the future.
In the view of Dr. Charles Li, Vice President of Angel Pharmaceutical Co., Ltd., the new R & D center in Jiaxing Science and technology city has realized the effective allocation of innovation resources to the maximum extent, which is conducive to accelerating the progress of new drug development and listing and seizing the global pharmaceutical industry market. In the future, Angel Pharmaceutical will focus on innovative drugs for anti-tumor and autoimmune diseases. Make full use of Jiaxing's geographical, talent and industrial policy advantages on the G60 scientific and technological innovation corridor in the Yangtze River Delta to attract more talents.
Recent years, with Jiaxing Science and Technology Zone as the main platform, Nanhu District takes the biomedical industry as an important part of the modern industrial system of the whole district, and takes advantage of the location advantages of the key nodes of G60 science and technology innovation corridor, and takes the biomedical industry as a new "window" for development, opening a new chapter of high-quality development. The biomedical industrial park of Jiaxing Science and technology city has a planned area of about 5.5 square kilometers, focusing on the development of biomedical frontier industries mainly including biopharmaceuticals, medical devices and medical testing, and has been listed as one of the high-energy industrial ecological parks in Jiaxing City. At present, there are 104 biomedical industry enterprises. In 2020, the total output value of biomedical industry will reach 9.145 billion RMB.
During the event, Angel pharmaceutical also signed strategic cooperation agreements with Tigermed and Guanhe respectively.
Editor Zhang tinghong
Responsible editor Luo Jia
Reviewed by Jin zhoubin
Jiaguang group media news center
